Software Engineer - Platform
About the job
- 8+ years of post-college experience in software engineering, platform engineering, or a related field.
- Proficiency in Python or similar programming languages.
- Experience building and scaling distributed systems, application programming interfaces, and cloud infrastructure.
- Hands-on experience with containerization, orchestration, and continuous integration/continuous delivery pipelines.
- Understanding of database design and performance optimization.
- Experience with cloud platforms such as Amazon Web Services, Google Cloud Platform, or Microsoft Azure, and infrastructure as code.
- A systems-oriented approach and passion for building reliable, maintainable infrastructure.
- Ability to navigate ambiguity and rapidly evolving technical requirements.
- Curiosity about applying artificial intelligence infrastructure to the life sciences industry.
- Thoroughness and precision in system design and implementation.
- Build and maintain Bluenote's core platform infrastructure, including application programming interfaces, data pipelines, retrieval-augmented generation, and an agent orchestrator.
- Design scalable architectures that support enterprise-grade artificial intelligence workflows and agent orchestration.
- Develop tooling and frameworks that enable rapid development and deployment of artificial intelligence solutions.
- Implement monitoring, logging, and observability systems to ensure platform reliability.
- Collaborate with the Agent Engineering team to understand platform requirements and optimize for its use cases.
- Own platform security, performance, and scalability as the customer base grows.
- Prior experience with machine learning/artificial intelligence infrastructure, LLMOps, or data engineering is a strong plus.
About the company
Bluenote Health provides an AI-powered platform for life sciences regulatory and compliance workflows. Its system automates tasks like copy-paste and content synthesis for regulatory documents (CSRs, CMCs, AV reports) by orchestrating hundreds of language model calls and algorithms to improve document quality and accuracy. The platform can be hosted within a client’s own IT environment and is built to meet strict security standards (HIPAA, GDPR, SOC2, CLIA, CAP), giving customers maximum control over data. What sets Bluenote apart is its focus on life sciences use cases, emphasis on document quality, and the ability to run within clients’ infrastructures to support critical regulatory work. The company’s goal is to help life sciences companies bring medicines, medical devices, and diagnostics to patients faster by accelerating regulatory processes and enabling compliant, high-quality documentation.
Company Size
11-50
Company Stage
Early VC
Total Funding
$10M
Headquarters
San Francisco, California
Founded
2022
Get referred to Bluenote
See people who can refer or advise you
Simplify's Take
What believers are saying
- CMIC expects up to 75% faster documentation, creating a strong near-term proof point.
- Japanese CRO adoption opens APAC expansion across sponsors needing faster regulatory submissions.
- Hosted-within-customer-infrastructure and SOC2, HIPAA, GDPR positioning lowers adoption friction for hospitals and pharma.
What critics are saying
- CMIC concentration creates customer-power risk if the partnership stalls in 2026.
- $10M funding cannot finance prolonged enterprise sales against Veeva, Microsoft, and OpenAI ecosystems.
- Clinical and regulatory AI invites validation failures, exposing Bluenote to compliance disputes and trust collapse.
What makes Bluenote unique
- CMIC partnership in March 2026 validates Bluenote's clinical-documentation workflow depth.
- Bluenote targets regulated life-sciences writing across protocols, CSRs, eCTD, and CMC documents.
- $10M December 2024 financing from Lux Capital, Anthropic, and Elad Gil signaled elite backing.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
29%1 year growth
29%2 year growth
15%CMIC, a contract research organisation jointly owned by Blackstone and CMIC HOLDINGS, has partnered with Bluenote to deploy agentic AI across clinical development operations. The collaboration aims to enhance speed, quality and scalability of clinical trials and regulatory submissions for biopharma sponsors. Bluenote's AI platform supports documentation across all development stages, including protocols, statistical analysis plans and clinical study reports, whilst maintaining compliance with global regulatory requirements from ICH, FDA, PMDA and EMA. CMIC expects the technology to accelerate select regulatory and clinical documentation processes by up to 75%. As one of Japan's largest CROs with over 30 years' experience, CMIC will integrate Bluenote's AI agents across end-to-end clinical development workflows to support pharmaceutical companies across APAC and worldwide.
Bluenote raises $10M to revolutionize life sciences workflows with generative AI.